68Ga-citrate

Philogen Provides Corporate Update 211 out of 214 patients recruited in European Phase III trial investigating the neoadjuvant Nidlegy™ treatment of Stage IIIB/C melanoma, in line with expectations. Fibromun further demonstrates potent activity in recurrent glioblastoma with durable major responses. Pivotal clinical trials in soft-tissue sarcoma and glioblastoma are on track. OncoFAP showspotent activity as a small molecule-drug conjugate. 177Lu-BiOncoFAP therapy shown to eradicate cancer in pre-clinical studies. Signed contract with Senn Chemicals for the GMP manufacturing of the product. Clinical trials expected to start in 2H 2023. Limited or no cash burn expected in 2022 due to existing and new partnerships, despite increased spending for clinical trials. Philogen’s management team will hold a webinar to discuss these updates onJune23, 2022, at 10:00 ET / 15:00 BST / 16:00 CEST (Please find the link to this webinar here). Siena (Italy), 23June 2022 - Philogen S.p.A., a clinical-stage biotechnology company focused on antibody- and small molecule-based targeted therapeutics, provides an update regarding recent corporate developments. Prof. Dr. Dario Neri, Chief Executive Officer of Philogen commented:"Philogen has made significant progress over the past few monthsas we continue investing ourIPO proceeds to strengthenour GMP manufacturing capacity and speed up patient enrolment in clinical trials. We are particularly pleased with the progress of ourPhase III European study investigating Nidlegy™ treatment of Stage IIIB/C melanoma, of which we have nearly completed patient recruitment. Fibromun’s trials in soft-tissue sarcoma are also ongoing in the U.S., Germany, Poland, Spain, and Italy (France planned), with the participation of leading clinical centers. We expect to have more than30 active clinical centers by the end of this year for the European and USpivotal studies. My thanks go to our investors and to everyone at Philogen for their hard work and unwavering support.” MAIN EVENTS AND RECENT HIGHLIGHTS Proprietary products Nidlegy™ is a pharmaceutical product, proprietary to Philogen, consisting of two active ingredients, L19IL2 and L19TNF. The L19 antibody is specific to the B domain of Fibronectin, a protein expressed in tumors (and other diseases) but absent in most healthy tissues. Interleukin 2 (IL2) and Tumor Necrosis Factor (TNF) are inflammatory cytokines with anti-tumor activities Phase III European study in Stage IIIB/C melanoma 211 out of 214 patients have been recruited. The trial will read when 95 events (tumor recurrence or patient death) have occurred, as per protocol 21 clinical centers opened in Germany, France, Italy, and Poland Phase III U.S. study in Stage IIIB/C melanoma 13 clinical sites are currently open. We expect to have more than 25 centers active by the end of 2022 to speed up recruitment Non-melanoma skin cancer Progress in Phase II studies ongoing in France, Germany, Poland, and soon in Italy Fibromun (L19TNF) is a pharmaceutical product, proprietary to Philogen, consisting of the L19 antibody fused to TNF European Phase III study in metastatic/advanced soft-tissue sarcoma 32 patients have been recruited. The recruitment rate of patients is progressing according to planned timelines 10 clinical centers opened in Germany, Spain, Italy, and Poland. We expect to have more than 20 centers active by the end of 2022 Phase I/II study in glioblastoma at first progression The Phase I dose escalation part of the study is exploring different doses of Fibromun and Lomustine (3-6 subjects per cohort) Cohort 1 has been completed with 6 patients. Recruitment for cohort 2 is ongoing, with 4 out of 6 patients recruited. The historical objective response rate (ORR) for recurrent glioblastoma treated with Lomustine is 4.3-13.9%. The median progression free survival of these patients with lomustine monotherapy is 6 weeks. In unmethylated MGMT tumors, objective responses are virtually never observed (0% ORR) (Wick et al., J Clin Oncol 2010, 28,1168; Weller and Le Rhun et al., Cancer Treat Rev 2020, 87,102029). In cohort 1, we observed durable major responses in 2 out of 6 patients which are ongoing for more than 12 months. In addition, 3 patients had disease stabilization for over 4.5 months (follow up ongoing), while one patient had Covid-19 and had to exit the study without receiving the combination treatment. OncoFAP is a small organic molecule ligand with ultra-high affinity for Fibroblast Activation Protein (FAP) OncoFAP-radio conjugates Imaging - excellent targeting properties of 68Ga-DOTAGA-OncoFAP confirmed in more than 50 patients with various types of malignancies. Therapy – 177Lu-DOTAGA-BiOncoFAP, featuring a bivalent OncoFAP ligand, cures cancer in murine models and has been identified as the therapeutic candidate for clinical development. Signed a contract with Senn Chemicals to manufacture DOTAGA-BiOncoFAP OncoFAP-drug conjugates – these drugs consist of (i) the OncoFAP ligand, (ii) a cleavable linker and (iii) a cytotoxic payload, which is released selectively at the tumor site. A novel OncoFAP-drug conjugate, featuring an optimized cleavable linker, is being studied in animal models of cancer and may represent a novel potential clinical candidate. The R&D center in Zürich has recently generated promising novel prototypes, including a highly active small molecule drug conjugate targeting PSMA. The company is well poised for the definition of the clinical candidates to be moved into the clinic in 2023. * * * Philogen Group Description Philogen is an Italian-Swiss company active in the biotechnology sector, specialized in the research and development of pharmaceutical products for the treatment of highly lethal diseases. The Group mainly discovers and develops targeted anticancer drugs, exploiting high-affinity ligands for tumor markers (also called tumor antigens). These ligands - human monoclonal antibodies or small organic molecules - are identified using Antibody Phage Display Libraries and DNA-EncodedChemical Library technologies. The Group's main therapeutic strategy for the treatment of these diseases is represented by the so-called tumor targeting. This approach is based on the use of ligands capable of selectively delivering very potent therapeutic active ingredients (such as pro-inflammatory cytokines) to the tumor mass, sparing healthy tissues. Over the years, Philogen has mainly developed monoclonal antibody-based ligands that are specific for antigens expressed in tumor-associated blood vessels, but not expressed in blood vessels associated with healthy tissues. These antigens are usually more abundant and more stable than those expressed directly on the surface of tumor cells. This approach, so called vascular targeting, is used for most of the projects pursued by the Group. The Group's objective is to generate, develop and market innovative products for the treatment of diseases for which medical science has not yet identified satisfactory therapies. This is achieved by exploiting (i) proprietary technologies for the isolation of ligands that react with antigens present in certain diseases, (ii) experience in the development of products targeted at the tissues affected by the disease, (iii) experience in drug manufacturing and development, and (iv) an extensive portfolio of patents and intellectual property rights. Although the Group's drugs are primarily oncology applications, the targeting approach is also potentially applicable to other diseases, such as certain chronic inflammatory diseases. * * * FOR MORE INFORMATION: Philogen - Investor Relations IR@philogen.com - Emanuele Puca | Investor Relations Consilium Strategic Communications contacts Mary-Jane Elliott, Davide Salvi Philogen@consilium-comms.com

June 9, 2022 12:30 UTC BURLINGTON, Mass. & OXFORD, England--(BUSINESS WIRE)-- Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced upcoming presentations at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, to be held June 11 – 14, 2022 in Vancouver, British Columbia, Canada. Presentations on investigational radiohybrid Prostate-Specific Membrane Antigen (rhPSMA) compounds are being made at the conference. They include additional results from the Company’s Phase 3 SPOTLIGHT study (NCT04186845) evaluating the safety and diagnostic performance of 18F-rhPSMA-7.3 PET imaging in men with suspected prostate cancer recurrence based on elevated PSA following prior therapy, and preclinical evaluation of 177Lu-rhPSMA-10.1, being investigated by Blue Earth Therapeutics as a therapeutic radiopharmaceutical candidate for prostate cancer. Presentations on investigational studies of 18F-fluciclovine include an interim report from an exploratory trial in lobular breast cancer, distinguishing pseudoprogression from tumor recurrence in glioblastoma, and amino acid transport mechanisms and staging in muscle invasive bladder cancer. Details of selected oral and poster presentations by Blue Earth Diagnostics and its collaborators are listed below. NOTE: Currently, rhPSMA compounds are investigational and have not received regulatory approval. 18F-fluciclovine is an approved molecular imaging radiopharmaceutical for use in PET imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment. Presentations noted by “*” discuss results of investigational studies of an approved product that is not approved by the FDA for the specific use or purpose noted. Investigational rhPSMA Oral presentations 18F-rhPSMA-7.3 Tuesday, June 14, 2022 Title: Inter- and intra-reader reproducibility of 18F-rhPSMA-7.3 PET image interpretation in patients with suspected prostate cancer recurrence: Results from a phase 3, prospective, multicenter study (SPOTLIGHT) Presenter: Phillip Kuo, MD, Ph.D., Departments of Medical Imaging, Medicine, and Biomedical Engineering, University of Arizona, Tucson, Ariz. and Invicro, Boston, Mass., on behalf of the SPOTLIGHT study group Session Title: SS 33 -PSMA-targeted imaging Session Time: 10:00 – 11:30 AM PT Presentation: 10:20 – 10:30 AM PT Room: 118/119/120 Program ID: 2539 177Lu-rhPSMA-10.1 Monday, June 13, 2022 Title: Preclinical evaluation of a novel radioligand therapy for patients with prostate cancer: biodistribution and efficacy of 177Lu-rhPSMA-10.1 in comparison with 177Lu-PSMA-I&T Presenter: Caroline Foxton, Ph.D., Blue Earth Therapeutics, Oxford, UK Session Title: SS 16 Radiotherapy and Radiotheranostics Session Time: 10:00 – 11:30 AM PT Presentation: 10:50 AM – 11:00 AM PT Room: 114/115 Program ID: 2567 Axumin® (fluciclovine F 18) and Investigational 18F-fluciclovine Oral presentation Sunday, June 12, 2022 Title: 18F-Fluciclovine and 68Ga-PSMA-11 PET/CT for Detection of Invasive Lobular Breast Cancer: Interim Report from an Exploratory Trial* Presenter: David M. Schuster, MD, FACR, Winship Cancer Institute of Emory University, Atlanta, Ga. Session Type: Oral Session Title: SS 09 - Thoracic Malignancies: Breast and Lung Session Time: 12:30 – 2:00 PM PT Presentation: 1:10 – 1:20 PM PT Room: 114/115 Program ID: 2592 Poster Award Candidate Presentation The poster, 18F-fluciclovine PET and multi-parametric MRI to distinguish pseudoprogression from tumor progression in post-treatment glioblastoma*, has been selected as a Poster Award Candidate by SNMMI and will be presented in an oral presentation on Monday, June 13, 2022 at 3:00 PM PT in the Poster Hall. All SNMMI poster presentations are available beginning Saturday, June 11, 2022 at 6:00 PM PT in Exhibit Hall A. Title: Detection rates from 18F-fluciclovine total-body PET/CT in prostate cancer patients with biochemical recurrence Presenter: Yasser Abdelhafez, MD, Research Specialist, University of California Davis, Davis, Calif. Program ID: 3042 Title: Fluciclovine-PET assessment of amino-acid transporter kinetics for primary staging of muscle-invasive bladder cancer* Presenter: Arda Konik,Ph.D., Instructor in Radiology, Department of Radiology, Dana Farber Cancer Institute, Boston, Mass. Program ID: 3053 Abstract ID: 634 Title: 18F-fluciclovine PET and multi-parametric MRI to distinguish pseudoprogression from tumor progression in post-treatment glioblastoma* Presenter: Ali Nabavizadeh, MD, Assistant Professor of Radiology, University of Pennsylvania Health System, Philadelphia, Pa. Program ID: 3108 Abstract ID: 809 Title: Pilot Study of 18F-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Before Radical Cystectomy: Preliminary Results* Presenter: Thomas Ng, MD, Ph.D., Instructor, Radiology, Harvard Medical School, Boston, Mass. Program ID: 3052 Abstract ID: 604 Blue Earth Diagnostics invites participants at the 2022 SNMMI Annual Meeting to attend the presentations above and to visit the Company at Exhibit Booth 1419. The Company is hosting a Satellite Symposium, “18F-rhPSMA-7.3, a Unique Investigational Prostate-specific Membrane Antigen (PSMA)-targeted PET Imaging Agent for Men with Prostate Cancer,” with invited speaker Dr. Andrei Purysko, MD, Department of Diagnostic Radiology, Cleveland Clinic, Cleveland, Ohio. Additional speakers include David Gauden, D.Phil., Chief Executive Officer, and Eugene M. Teoh, MBBS, MRCP, FRCR, D.Phil., Chief Medical Officer, of Blue Earth Diagnostics. The event will be held on Sunday, June 12, 2022, from 11:15 a.m. – 12:15 p.m. PT in Ballroom C (East Building) of the Vancouver Convention Center. For full session details and scientific presentation lists, please see the SNMMI online program HERE. Indication and Important Safety Information About Axumin INDICATION Axumin® (fluciclovine F 18) injection is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment. IMPORTANT SAFETY INFORMATION Image interpretation errors can occur with Axumin PET imaging. A negative image does not rule out recurrent prostate cancer and a positive image does not confirm its presence. The performance of Axumin seems to be affected by PSA levels. Axumin uptake may occur with other cancers and benign prostatic hypertrophy in primary prostate cancer. Clinical correlation, which may include histopathological evaluation, is recommended. Hypersensitivity reactions, including anaphylaxis, may occur in patients who receive Axumin. Emergency resuscitation equipment and personnel should be immediately available. Axumin use contributes to a patient’s overall long-term cumulative radiation exposure, which is associated with an increased risk of cancer. Safe handling practices should be used to minimize radiation exposure to the patient and health care providers. Adverse reactions were reported in ≤ 1% of subjects during clinical studies with Axumin. The most common adverse reactions were injection site pain, injection site erythema and dysgeusia. To report suspected adverse reactions to Axumin, call 1-855-AXUMIN1 (1-855-298-6461) or contact FDA at 1-800-FDA-1088 or . Full Axumin prescribing information is available at . About Blue Earth Diagnostics Blue Earth Diagnostics, an indirect subsidiary of Bracco Imaging S.p.A., is a growing international molecular imaging company focused on delivering innovative, well-differentiated diagnostic solutions that inform patient care. Formed in 2014, the Company’s success is driven by its management expertise and supported by a demonstrated track record of rapid development and commercialization of positron emission tomography (PET) radiopharmaceuticals. Blue Earth Diagnostics’ expanding oncology portfolio encompasses a variety of disease states, including prostate cancer and neuro-oncology. Blue Earth Diagnostics is committed to the timely development and commercialization of precision radiopharmaceuticals for potential use in imaging and therapy. For more information, please visit: . About Bracco Imaging Bracco Imaging S.p.A., part of the Bracco Group, is a world-leading diagnostic imaging provider. Headquartered in Milan, Italy, Bracco Imaging develops, manufactures and markets diagnostic imaging agents and solutions. It offers a product and solution portfolio for all key diagnostic imaging modalities: X-ray imaging (including Computed Tomography-CT, Interventional Radiology, and Cardiac Catheterization), Magnetic Resonance Imaging (MRI), Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine through radioactive tracers and novel PET imaging agents to inform clinical management and guide care for cancer patients in areas of unmet medical need. Our continually evolving portfolio is completed by a range of medical devices, advanced administration systems and dose-management software. In 2019 Bracco Imaging enriched its product portfolio by expanding the range of oncology nuclear imaging solutions in the urology segment and other specialties with the acquisition of Blue Earth Diagnostics. In 2021, Bracco Imaging established Blue Earth Therapeutics as a separate, cutting-edge biotechnology vehicle to develop radiopharmaceutical therapies. Visit: .